SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Adherence to the iDSI reference case among published cost-per-DALY averted studies
16 references·1 citing·30 second hop
Adherence to the iDSI reference case among published cost-per-DALY averted studies (2019)Adherence to the iDSI reference case amon…Dreamtime: Version 5.0 of the Australian Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (2017)Dreamtime: Version 5.0 of the…The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought (2016)The International Decision Su…Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Recommendations for Conduct, …Priority-setting for achieving universal health coverage (2016)Priority-setting for achievin…Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Consolidated Health Economic …Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement (2013)Consolidated Health Economic …Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Consolidated Health Economic …Priority-Setting Institutions in Health: Recommendations from a Center for Global Development Working Group (2012)Priority-Setting Institutions…National Institute for Clinical Excellence and its value judgments (2004)National Institute for Clinic…Making choices in health: who guide to cost-effectiveness analysis (2004)Making choices in health: who…Generalisability in economic evaluation studies in healthcare: a review and case studies (2004)Generalisability in economic …Development of WHO guidelines on generalized cost-effectiveness analysis (2000)Development of WHO guidelines…The Role of Cost-Effectiveness Analysis in Health and Medicine (1997)The Role of Cost-Effectivenes…The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The Role of Cost-effectivenes…Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel …PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (1958)PHARMACEUTICAL BENEFITS ADVIS…Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations (2022)Consolidated Health Economic …Bulletin of the World Health Organization (1955)Cost-Effectiveness in Health and Medicine (1996)Generalized cost-effectiveness analysis for national-level priority-setting in the health sector (2003)Methods for the Economic Evaluation of Health Care Programmes (2005)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)EuroQol - a new facility for the measurement of health-related quality of life (1990)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (1992)Recommendations for Reporting Cost-effectiveness Analyses (1996)Criteria for evaluating evidence on public health interventions (2002)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)EuroQol: the current state of play (1996)Systematic reviews in the social sciences: a practical guide (2006)Delivering affordable cancer care in high-income countries (2011)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement (2016)Methods for the economic evaluation of health care programmes (1987)Developing Criteria for Health Economic Quality Evaluation Tool (2023)Projected health and economic impacts of sugar-sweetened beverage taxation in Germany: A cross-validation modelling study (2023)The economic burden of coronary heart disease in mainland China (2023)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Health outcomes in economic evaluation: the QALY and utilities (2010)A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial (2012)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? (2020)Understanding Costs of Care in the Operating Room (2018)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force (2022)Exploratory Research (2020)
this work references cited by second hop

References

  • 2016Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses3,139 cited
  • 1996Recommendations of the Panel on Cost-Effectiveness in Health and Medicine2,507 cited
  • 2013Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force2,025 cited
  • 2013Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement1,790 cited
  • 1996The Role of Cost-effectiveness Analysis in Health and Medicine1,277 cited
  • 2004Making choices in health: who guide to cost-effectiveness analysis1,259 cited
  • 2004National Institute for Clinical Excellence and its value judgments767 cited
  • 2013Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement657 cited
  • 2000Development of WHO guidelines on generalized cost-effectiveness analysis578 cited
  • 2004Generalisability in economic evaluation studies in healthcare: a review and case studies441 cited
  • 2016The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought328 cited
  • 1958PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE255 cited
  • 2016Priority-setting for achieving universal health coverage167 cited
  • 1997The Role of Cost-Effectiveness Analysis in Health and Medicine

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

114 cited
  • 2017Dreamtime: Version 5.0 of the Australian Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC)99 cited
  • 2012Priority-Setting Institutions in Health: Recommendations from a Center for Global Development Working Group98 cited
  • Cited by

    • 2022Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations1,200 cited